{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:45:46Z","timestamp":1776671146683,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"New Technology of Clinical Diagnosis and Treatment Project of Jinling Hospital","award":["2023LCZLXB044"],"award-info":[{"award-number":["2023LCZLXB044"]}]},{"name":"A Study on the Cognitive Attitude, Current Status and Influencing Factors of Elderly Inpatients with Chronic Diseases towards Advance Care Planning","award":["HBRCGL04"],"award-info":[{"award-number":["HBRCGL04"]}]},{"name":"Key Project of Nanjing Medical Science and Technology Development Program","award":["ZKX23037"],"award-info":[{"award-number":["ZKX23037"]}]},{"name":"Key Project of Talent Cultivation Program of Nanjing Second Hospital","award":["RCZD202302"],"award-info":[{"award-number":["RCZD202302"]}]},{"name":"General Project of the Special Research Program for Post-marketing Clinical Research of Innovative Drugs of the National Health Commission","award":["WKZX2024CX101211"],"award-info":[{"award-number":["WKZX2024CX101211"]}]},{"name":"the Clinical Diagnosis and Treatment New Technology Project","award":["22LCZLXJS58"],"award-info":[{"award-number":["22LCZLXJS58"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-41718-6","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:45:23Z","timestamp":1773121523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The E3 ubiquitin ligase RNF180 modulates the EGFR\/PI3K\/AKT pathway to reduce cisplatin resistance in non-small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1022-4015","authenticated-orcid":false,"given":"Xiaoyan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2829-1676","authenticated-orcid":false,"given":"Hongxuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0145-9366","authenticated-orcid":false,"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7040-812X","authenticated-orcid":false,"given":"Chuandong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1576-9126","authenticated-orcid":false,"given":"Fangfang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"41718_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L. et al. Cancer statistics, 2024, CA: A Cancer Journal for Clinicians, 74, 1, pp. 12\u201349, (2024). https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"issue":"10308","key":"41718_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398 (10308), 1344\u20131357. https:\/\/doi.org\/10.1016\/S0140-6736(21)02098-5 (2021).","journal-title":"Lancet"},{"issue":"2","key":"41718_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. J. Med. 346 (2), 92\u201398. https:\/\/doi.org\/10.1056\/NEJMoa011954 (2002).","journal-title":"N Engl. J. Med."},{"issue":"15","key":"41718_CR4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31 (15), 1869\u20131883. https:\/\/doi.org\/10.1038\/onc.2011.384 (2012).","journal-title":"Oncogene"},{"issue":"4","key":"41718_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/cncr.26189","volume":"118","author":"K Cheung","year":"2012","unstructured":"Cheung, K. et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer 118 (4), 947\u2013959. https:\/\/doi.org\/10.1002\/cncr.26189 (2012).","journal-title":"Cancer"},{"issue":"8","key":"41718_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/PL00000762","volume":"57","author":"P Jordan","year":"2000","unstructured":"Jordan, P. et al. Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 57 (8), 1229\u20131235. https:\/\/doi.org\/10.1007\/PL00000762 (2000).","journal-title":"Cell. Mol. Life Sci."},{"key":"41718_CR7","doi-asserted-by":"publisher","unstructured":"Ogawa, M. et al. Rines\/RNF180, a novel RING finger gene-encoded product, is a membrane bound ubiquitin ligase. Genes Cells. 13 (4), 397\u2013409. https:\/\/doi.org\/10.1111\/j.1365-2443.2008.01169.x (2008).","DOI":"10.1111\/j.1365-2443.2008.01169.x"},{"key":"41718_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell. Biol. 10, 550\u2013563. https:\/\/doi.org\/10.1038\/nrm2731 (2009).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"8","key":"41718_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00109-022-02229-9","volume":"100","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Functional roles of E3 ubiquitin ligases in prostate cancer. J. Mol. Med. 100 (8), 1125\u20131144. https:\/\/doi.org\/10.1007\/s00109-022-02229-9 (2022).","journal-title":"J. Mol. Med."},{"issue":"1","key":"41718_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13148-015-0077-1","volume":"7","author":"S Udali","year":"2015","unstructured":"Udali, S. et al. DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma. Clin. Epigenetics. 7 (1), 43. https:\/\/doi.org\/10.1186\/s13148-015-0077-1 (2015).","journal-title":"Clin. Epigenetics"},{"issue":"2","key":"41718_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00109-020-02015-5","volume":"99","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance. J. Mol. Med. 99 (2), 193\u2013212. https:\/\/doi.org\/10.1007\/s00109-020-02015-5 (2021).","journal-title":"J. Mol. Med."},{"key":"41718_CR12","doi-asserted-by":"publisher","first-page":"623455","DOI":"10.3389\/fcell.2020.623455","volume":"8","author":"F Wei","year":"2021","unstructured":"Wei, F. et al. RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1. Front. Cell. Dev. Biol. 8, 623455. https:\/\/doi.org\/10.3389\/fcell.2020.623455 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"41718_CR13","doi-asserted-by":"publisher","unstructured":"L. P et al., E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. Chemico-Biol. Interact., 354, (2022). https:\/\/doi.org\/10.1016\/j.cbi.2022.109798","DOI":"10.1016\/j.cbi.2022.109798"},{"key":"41718_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature04177","volume":"439","author":"RB Jones","year":"2006","unstructured":"Jones, R. B. et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168\u2013174. https:\/\/doi.org\/10.1038\/nature04177 (2006).","journal-title":"Nature"},{"issue":"2","key":"41718_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori, T. et al. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury. Int. J. Mol. Sci. 22 (2), 792. https:\/\/doi.org\/10.3390\/ijms22020792 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"41718_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41422-018-0079-6","volume":"28","author":"L He","year":"2018","unstructured":"He, L. et al. Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR\/PI3K\/AKT drives breast carcinogenesis. Cell. Res. 28 (9), 934\u2013951. https:\/\/doi.org\/10.1038\/s41422-018-0079-6 (2018).","journal-title":"Cell. Res."},{"issue":"6616","key":"41718_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/385544a0","volume":"385","author":"A Kauffmann-Zeh","year":"1997","unstructured":"Kauffmann-Zeh, A. et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385 (6616), 544\u2013548. https:\/\/doi.org\/10.1038\/385544a0 (1997).","journal-title":"Nature"},{"issue":"2","key":"41718_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3892\/or.2012.2131","volume":"29","author":"M Chen","year":"2013","unstructured":"Chen, M. et al. Ophiopogonin B-induced autophagy in non-small cell lung cancer cells via inhibition of the PI3K\/Akt signaling pathway. Oncol. Rep. 29 (2), 430\u2013436. https:\/\/doi.org\/10.3892\/or.2012.2131 (2013).","journal-title":"Oncol. Rep."},{"key":"41718_CR19","doi-asserted-by":"publisher","unstructured":"Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 8, pp. 735\u2013742, (2011). https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X","DOI":"10.1016\/S1470-2045(11)70184-X"},{"issue":"3","key":"41718_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","volume":"13","author":"T Ciuleanu","year":"2012","unstructured":"Ciuleanu, T. et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13 (3), 300\u2013308. https:\/\/doi.org\/10.1016\/S1470-2045(11)70385-0 (2012).","journal-title":"Lancet Oncol."},{"key":"41718_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo, F. et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11, 521\u2013529. https:\/\/doi.org\/10.1016\/S1470-2045(10)70112-1 (2010).","journal-title":"Lancet Oncol."},{"issue":"2","key":"41718_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.lungcan.2012.03.012","volume":"77","author":"YL Wu","year":"2012","unstructured":"Wu, Y. L. et al. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer. 77 (2), 339\u2013345. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.012 (2012).","journal-title":"Lung Cancer"},{"key":"41718_CR23","doi-asserted-by":"publisher","unstructured":"C. F et al., Knocking down of Polo-like kinase 2 inhibits cell proliferation and induces cell apoptosis in human glioma cells. Life Sci., 270, (2021). https:\/\/doi.org\/10.1016\/j.lfs.2021.119084","DOI":"10.1016\/j.lfs.2021.119084"},{"issue":"4","key":"41718_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/bjs.10066","volume":"103","author":"J Deng","year":"2016","unstructured":"Deng, J. et al. Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer. Br. J. Surg. 103 (4), 407\u2013416. https:\/\/doi.org\/10.1002\/bjs.10066 (2016).","journal-title":"Br. J. Surg."},{"key":"41718_CR25","doi-asserted-by":"publisher","unstructured":"L. H et al., Ring finger protein 180 is associated with biological behavior and prognosis in patients with non-small cell lung cancer. Oncol. Lett., 20, 4, (2020). https:\/\/doi.org\/10.3892\/ol.2020.11898","DOI":"10.3892\/ol.2020.11898"},{"key":"41718_CR26","doi-asserted-by":"publisher","unstructured":"D. Y et al., Ring finger protein 180 suppresses cell proliferation and energy metabolism of non-small cell lung cancer through downregulating C-myc. World J. Surg. Oncol., 20, 1, (2022). https:\/\/doi.org\/10.1186\/s12957-022-02599-x","DOI":"10.1186\/s12957-022-02599-x"},{"issue":"7","key":"41718_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.stem.2024.04.017","volume":"31","author":"S Stelloo","year":"2024","unstructured":"Stelloo, S. et al. Deciphering lineage specification during early embryogenesis in mouse gastruloids using multilayered proteomics. Cell. Stem Cell. 31 (7), 1072\u20131090. https:\/\/doi.org\/10.1016\/j.stem.2024.04.017 (2024).","journal-title":"Cell. Stem Cell."},{"issue":"1","key":"41718_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.15252\/msb.20156423","volume":"12","author":"Z Cheng","year":"2016","unstructured":"Cheng, Z. et al. Differential dynamics of the mammalian mRNA and protein expression response to misfolding stress. Mol. Syst. Biol. 12 (1), 855. https:\/\/doi.org\/10.15252\/msb.20156423 (2016).","journal-title":"Mol. Syst. Biol."},{"issue":"4","key":"41718_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/19336918.2015.1016686","volume":"9","author":"W Xu","year":"2015","unstructured":"Xu, W. et al. A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition. Cell. Adh Migr. 9 (4), 317\u2013324. https:\/\/doi.org\/10.1080\/19336918.2015.1016686 (2015).","journal-title":"Cell. Adh Migr."},{"issue":"1","key":"41718_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","volume":"8","author":"AK Nanayakkara","year":"2018","unstructured":"Nanayakkara, A. K. et al. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci. Rep. 8 (1), 967. https:\/\/doi.org\/10.1038\/s41598-018-19325-x (2018).","journal-title":"Sci. Rep."},{"issue":"2","key":"41718_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood.V79.2.473.473","volume":"79","author":"L Campos","year":"1992","unstructured":"Campos, L. et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 (2), 473\u2013476. https:\/\/doi.org\/10.1182\/blood.V79.2.473.473 (1992).","journal-title":"Blood"},{"issue":"3","key":"41718_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/blood.V78.3.586.586","volume":"78","author":"JP Marie","year":"1991","unstructured":"Marie, J. P. et al. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78 (3), 586\u2013592. https:\/\/doi.org\/10.1182\/blood.V78.3.586.586 (1991).","journal-title":"Blood"},{"issue":"5","key":"41718_CR33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1245\/s10434-009-0395-7","volume":"16","author":"L Li","year":"2009","unstructured":"Li, L. et al. MDR1\/P-gp and VEGF Synergistically Enhance the Invasion of Hep-2 Cells with Multidrug Resistance Induced by Taxol. Ann. Surg. Oncol. 16 (5), 1421\u20131428. https:\/\/doi.org\/10.1245\/s10434-009-0395-7 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"41718_CR34","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2024","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2024).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"41718_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28 (1), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"41718_CR36","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong, C. R. et al. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19 (11), 1389\u20131400. https:\/\/doi.org\/10.1038\/nm.3388 (2013).","journal-title":"Nat. Med."},{"key":"41718_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s11658-018-0109-x","volume":"23","author":"MR Abbaszadegan","year":"2018","unstructured":"Abbaszadegan, M. R. et al. WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma. Cell. Mol. Biol. Lett. 23, 42. https:\/\/doi.org\/10.1186\/s11658-018-0109-x (2018).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"41718_CR38","doi-asserted-by":"publisher","unstructured":"Moghbeli, M. et al. ErbB1 and ErbB3 co-overexpression as a prognostic factor in gastric cancer. Biol. Res. 52 (1, p. 2, ). https:\/\/doi.org\/10.1186\/s40659-018-0208-1 (2019).","DOI":"10.1186\/s40659-018-0208-1"},{"key":"41718_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi, S. et al. Akt in cancer: Mediator and more. Semin Cancer Biol. 59, 80\u201391. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.002 (2019).","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"41718_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. et al. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer. 20 (2), 74\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0216-7 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"41718_CR41","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.2147\/OTT.S250396","volume":"13","author":"S Cao","year":"2020","unstructured":"Cao, S. et al. MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR\/PI3K\/AKT Signaling Pathway. Onco Targets Ther. 13, 7493\u20137502. https:\/\/doi.org\/10.2147\/OTT.S250396 (2020).","journal-title":"Onco Targets Ther."},{"issue":"3","key":"41718_CR42","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3892\/or.2018.6215","volume":"39","author":"B Li","year":"2018","unstructured":"Li, B. et al. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K\/Akt and JAK2\/STAT3 signaling pathway by targeting EGFR. Oncol. Rep. 39 (3), 1227\u20131234. https:\/\/doi.org\/10.3892\/or.2018.6215 (2018).","journal-title":"Oncol. Rep."},{"issue":"6","key":"41718_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.drup.2006.11.001","volume":"9","author":"KR Landis-Piwowar","year":"2006","unstructured":"Landis-Piwowar, K. R. et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Updates. 9 (6), 263\u2013273. https:\/\/doi.org\/10.1016\/j.drup.2006.11.001 (2006).","journal-title":"Drug Resist. Updates"},{"issue":"4","key":"41718_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek, K. N. et al. Ubiquitin modifications. Cell. Res. 26 (4), 399\u2013422. https:\/\/doi.org\/10.1038\/cr.2016.39 (2016).","journal-title":"Cell. Res."},{"key":"41718_CR45","doi-asserted-by":"publisher","unstructured":"Cao, L. et al. E3 ubiquitin ligase Listerin regulates macrophage cholesterol efflux and atherosclerosis by targeting ABCA1. J. Clin. Invest. e186509. https:\/\/doi.org\/10.1172\/JCI186509 (2025).","DOI":"10.1172\/JCI186509"},{"key":"41718_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12935-020-01397-3","volume":"20","author":"R Zhou","year":"2020","unstructured":"Zhou, R. et al. RNF181 modulates Hippo signaling and triple negative breast cancer progression. Cancer Cell. Int. 20, 291. https:\/\/doi.org\/10.1186\/s12935-020-01397-3 (2020).","journal-title":"Cancer Cell. Int."},{"key":"41718_CR47","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.4161\/cc.7.22.7071","volume":"7","author":"O Cizmecioglu","year":"2008","unstructured":"Cizmecioglu, O. et al. Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell. Cycle. 7, 3548\u20133555. https:\/\/doi.org\/10.4161\/cc.7.22.7071 (2008).","journal-title":"Cell. Cycle"},{"key":"41718_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrm1401","volume":"5","author":"FA Barr","year":"2004","unstructured":"Barr, F. A. et al. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell. Biol. 5, 429\u2013440. https:\/\/doi.org\/10.1038\/nrm1401 (2004).","journal-title":"Nat. Rev. Mol. Cell. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41718-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:53:33Z","timestamp":1776668013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41718-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41718-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have consented to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were approved by the Institutional Animal Care Committee, and all animal experimental procedures and ethical approval were obtained from the Ethics Committee (IACUC) of Eastern Theater Command General Hospital (Approval No. DZGZRDW240010).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"12850"}}